Scarab Genomics and Lonza have entered into a preferred marketing and sales agreement for Scarab Genomics’ Clean Genome(r) E. coli. Financial details of the contract were not disclosed.

Lonza will support Scarab Genomics’ business development activities and becomes the preferred marketing provider for the Clean Genome technology, giving Lonza customers full access to the platform for protein and plasmid DNA production. Additionally, Lonza and Scarab Genomics will work together to develop new cutting-edge microbial expression technologies.

“Lonza has a wealth of experience in developing and marketing novel expression solutions,” said Fred Blattner, chief executive officer of Scarab Genomics. “We’re extremely happy to be working with Lonza to bring the Clean Genome technology to a wider customer base.”

The optimized Clean Genome E. coli strain is designed to provide enhanced genetic stability, improved metabolic efficiency and improved production yields for therapeutic proteins, plasmid DNA, and vaccines, according to a joint statement.

“The Scarab Genomics technology is a stable, high-yielding platform that enables customers to lower their cost of goods and simplify their production process,” said Joachim Klein, head of Microbial Innovation and Strain Development for Lonza. “Lonza is very pleased to be able to offer this breakthrough microbial expression technology to our customers side by side with our existing XS Microbial Expression Technologies.”